These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 12505243)

  • 1. Sample size correction for treatment crossovers in randomized clinical trials with a survival endpoint.
    Porcher R; Lévy V; Chevret S
    Control Clin Trials; 2002 Dec; 23(6):650-61. PubMed ID: 12505243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of statistical issues with progression-free survival as an interval-censored time-to-event endpoint.
    Sun X; Li X; Chen C; Song Y
    J Biopharm Stat; 2013; 23(5):986-1003. PubMed ID: 23957511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Power calculation for clinical trials when the outcome is a composite ranking of survival and a nonfatal outcome.
    McMahon RP; Harrell FE
    Control Clin Trials; 2000 Aug; 21(4):305-12. PubMed ID: 10913806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sample size under the additive hazards model.
    McDaniel LS; Yu M; Chappell R
    Clin Trials; 2016 Apr; 13(2):188-98. PubMed ID: 26572562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sample size calculation for the proportional hazards cure model.
    Wang S; Zhang J; Lu W
    Stat Med; 2012 Dec; 31(29):3959-71. PubMed ID: 22786805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sample size calculation for the weighted rank statistics with paired survival data.
    Jung SH
    Stat Med; 2008 Jul; 27(17):3350-65. PubMed ID: 18205148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.
    Cook G; Ashcroft AJ; Cairns DA; Williams CD; Brown JM; Cavenagh JD; Snowden JA; Parrish C; Yong K; Cavet J; Hunter H; Bird JM; Pratt G; Chown S; Heartin E; O'Connor S; Drayson MT; Hockaday A; Morris TC;
    Lancet Haematol; 2016 Jul; 3(7):e340-51. PubMed ID: 27374467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determination of hazard ratio for progression-free survival considering the tumor assessment schedule in sample size calculation.
    Tanase T
    Pharm Stat; 2020 Mar; 19(2):126-136. PubMed ID: 32067336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and sample size estimation in clinical trials with clustered survival times as the primary endpoint.
    Xie T; Waksman J
    Stat Med; 2003 Sep; 22(18):2835-46. PubMed ID: 12953283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of error rates in single-arm versus randomized phase II cancer clinical trials.
    Tang H; Foster NR; Grothey A; Ansell SM; Goldberg RM; Sargent DJ
    J Clin Oncol; 2010 Apr; 28(11):1936-41. PubMed ID: 20212253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sample size determination for comparing several survival curves with unequal allocations.
    Halabi S; Singh B
    Stat Med; 2004 Jun; 23(11):1793-815. PubMed ID: 15160409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sample Size Calculation: Inaccurate A Priori Assumptions for Nuisance Parameters Can Greatly Affect the Power of a Randomized Controlled Trial.
    Tavernier E; Giraudeau B
    PLoS One; 2015; 10(7):e0132578. PubMed ID: 26173007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sample size adjustment designs with time-to-event outcomes: A caution.
    Freidlin B; Korn EL
    Clin Trials; 2017 Dec; 14(6):597-604. PubMed ID: 28795844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Type-II error rates (beta errors) of randomized trials in orthopaedic trauma.
    Lochner HV; Bhandari M; Tornetta P
    J Bone Joint Surg Am; 2001 Nov; 83(11):1650-5. PubMed ID: 11701786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A method for sequential analysis of survival data with nonproportional hazards.
    Sooriyarachchi MR; Whitehead J
    Biometrics; 1998 Sep; 54(3):1072-84. PubMed ID: 9750253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three-component cure rate model for nonproportional hazards alternative in the design of randomized clinical trials.
    Kim HT; Gray R
    Clin Trials; 2012 Apr; 9(2):155-63. PubMed ID: 22353928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subgroup detection and sample size calculation with proportional hazards regression for survival data.
    Kang S; Lu W; Song R
    Stat Med; 2017 Dec; 36(29):4646-4659. PubMed ID: 28791726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The fallacy of enrolling only high-risk subjects in cancer prevention trials: is there a "free lunch"?
    Baker SG; Kramer BS; Corle D
    BMC Med Res Methodol; 2004 Oct; 4():24. PubMed ID: 15461821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Authors' reply to comments on 'Sample size calculation for the proportional hazards cure model'.
    Wang S; Zhang J; Lu W
    Stat Med; 2015 Jul; 34(17):2578-80. PubMed ID: 26133747
    [No Abstract]   [Full Text] [Related]  

  • 20. Cyclophosphamide mobilization does not improve outcome in patients receiving stem cell transplantation for multiple myeloma.
    Dingli D; Nowakowski GS; Dispenzieri A; Lacy MQ; Hayman S; Litzow MR; Gastineau DA; Gertz MA
    Clin Lymphoma Myeloma; 2006 Mar; 6(5):384-8. PubMed ID: 16640814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.